The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …

Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …

Tyrosine kinase inhibitors were found to be clinically effective for treatment of patients with
certain subsets of cancers carrying somatic mutations in receptor tyrosine kinases. However …

The transforming growth factor β (TGF-β) pathway, which is well studied for its ability to
inhibit cell proliferation in early stages of tumorigenesis while promoting epithelial …

Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug
treatment and constitute a major cause of treatment failure. These cells are characterized by …

The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

The emergence of drug resistance is the most substantial challenge to the effectiveness of
anticancer therapies. Orthogonal approaches have revealed that a subset of cells, known as …

Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients
with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR …